Please login to the form below

Not currently logged in
Email:
Password:

niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

GSK gained dostarlimab from its $5.1bn acquisition of cancer specialist Tesaro, as well as PARP inhibitor Zejula (niraparib), which is approved across a number of indications including ovarian, fallopian tube

Latest news

More from news
Approximately 4 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...